Insights on the Neutropenia Treatment Global Market to 2026 - Featuring Amgen, Novartis & Pfizer Among Others -

DUBLIN--()--The "Global Neutropenia Treatment Market By Distribution channel, By Treatment, By Region, Industry Analysis and Forecast, 2020 - 2026" report has been added to's offering.

The global neutropenia treatment market size is expected to reach $18.9 billion by 2026, rising at a market growth of 6.5% CAGR during the forecast period.

Neutropenia is an abnormal condition characterized by a critically low level of circulating neutrophils, a type of WBC found in the blood. These cells make up the majority of circulating lymphocytes and help protect the body from infections caused by bacteria, viruses, and other pathogenic organisms. A decrease in the amount of neutrophil in the blood allows a patient to be vulnerable to infection and can also prove fatal. The condition, therefore, requires immediate prophylaxis.

Novel treatments combined with growing cases of chemotherapy-induced neutropenia are one of the primary drivers of market growth. In addition, the novel drug delivery strategy also increases patient convenience, leading to greater adherence to the patient and thereby stimulates the growth of the market. Moreover, since cancer is a known cause of developing neutropenia, increasing cases of chemotherapy for cancer treatment will be a growth driver for the neutropenia treatment market.

One of the new developments to gain momentum in the global neutropenia treatment market is the introduction of small molecules. The development of Plinabulin, a small molecule developed by BeyondSpring Pharmaceuticals with immune-boosting effects, is expected to revolutionize the therapeutic regimen for neutropenia. In addition to the immune-boosting effects, the Phase II studies have revealed much more beneficial anti-cancer effects of this molecule. Currently, there is a high demand for cost-effective drugs for treatment in the neutropenia treatment market. As a result, vendors are focused on the production of small molecules with lower processing costs than biologics.

Based on Distribution channel, the market is segmented into Retail pharmacies, Hospital pharmacies and Online pharmacies. Based on Treatment, the market is segmented into Colony-stimulating factor, Antibiotics, Antifungals and Antivirals. Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa.

Unique Offerings from the Publisher

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Key Topics Covered:

Chapter 1. Market Scope & Methodology

Chapter 2. Market Overview

2.1 Introduction

2.1.1 Overview

2.1.2 Market Composition and Scenario

2.2 Key Factors Impacting the Market

2.2.1 Market Drivers

2.2.2 Market Restraints

Chapter 3. Global Neutropenia Treatment Market by Distribution channel

3.1 Global Retail pharmacies Market by Region

3.2 Global Hospital pharmacies Market by Region

3.3 Global Online pharmacies Market by Region

Chapter 4. Global Neutropenia Treatment Market by Treatment

4.1 Global Colony-stimulating factor Market by Region

4.2 Global Antibiotics Market by Region

4.3 Global Antifungals Market by Region

4.4 Global Antivirals Market by Region

Chapter 5. Global Neutropenia Treatment Market by Region

5.1 North America Neutropenia Treatment Market

5.2 Europe Neutropenia Treatment Market

5.3 Asia Pacific Neutropenia Treatment Market

5.4 LAMEA Neutropenia Treatment Market

Chapter 6. Company Profiles

6.1 Amgen, Inc.

6.2 Novartis AG

6.3 Pfizer, Inc.

6.4 Teva Pharmaceutical Industries Ltd.

6.5 BeyondSpring, Inc.

6.6 Spectrum Pharmaceuticals, Inc.

6.7 Kyowa Kirin Co., Ltd. (Kirin Company)

6.8 Mylan N.V.

6.9 Cellerant Therapeutics, Inc.

6.10 Partner Therapeutics, Inc.

For more information about this report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900